NCT03181984View on ClinicalTrials.gov

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain

PHASE4CompletedINTERVENTIONAL
Enrollment

501

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

April 19, 2023

Study Completion Date

April 19, 2023

Conditions
Port-Wine Stain
Interventions
DRUG

Hemoporfin

Hemoporfin mediated photodynamic therapy

Trial Locations (7)

100034

Peking University First Hospital, Beijing

Unknown

The 2nd Affiliated Hospital of Harbin Medical University, Harbin

Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine, Shijiazhuang

Wuxi People's Hospital, Wuxi

West China Hospital, Sichuan University, Chengdu

PLA Army General Hospital, Beijing

Shanghai Dermatology Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

INDUSTRY

NCT03181984 - Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain | Biotech Hunter | Biotech Hunter